• Disease Overview
  • Synonyms
  • Signs & Symptoms
  • Causes
  • Affected Populations
  • Disorders with Similar Symptoms
  • Standard Therapies
  • Clinical Trials and Studies
  • References
  • Programs & Resources
  • Complete Report

Pure Red Cell Aplasia, Acquired

Print

Last updated: August 07, 2007
Years published: 1988, 1989, 1996, 1997, 1999, 2007


Disease Overview

Acquired Pure Red Cell Aplasia is a rare bone marrow disorder characterized by an isolated decline of red blood cells (erythrocytes) produced by the bone marrow. Affected individuals may experience fatigue, lethargy, and/or abnormal paleness of the skin (pallor). Acquired Pure Red Cell Aplasia may occur for unknown reasons (idiopathic) or as a primary autoimmune disorder. It is also believed that Acquired Pure Red Cell Aplasia may occur secondary to a tumor of the thymus gland (thyoma), viral infections, or certain drugs.

  • Next section >
  • < Previous section
  • Next section >

Synonyms

  • PRCA
  • Pure Red Blood Cell Aplasia
  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Signs & Symptoms

Acquired Pure Red Cell Aplasia is characterized by a decrease in the number of red blood cells produced in the bone marrow. Individuals with this disorder are deficient in the number of precursors of red blood cells (erythroblasts). Levels of the hormone erythropoietin that stimulates the bone marrow to produce red blood cells are usually elevated.

Affected individuals may experience fatigue, lethargy, and/or abnormal paleness of the skin (pallor).

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Causes

Acquired Pure Red Cell Aplasia is thought to be an autoimmune disorder possibly caused either by a tumor of the thymus gland, certain drugs or a viral infection. It is one of a group of bone marrow failure syndromes.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Affected populations

Acquired Pure Red Cell Aplasia is a rare disorder affecting males and females in equal numbers.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Standard Therapies

Acquired Pure Red Cell Aplasia usually goes into remission when certain drugs such as sulfonylureas (used for treating diabetes), gold for treatment of arthritis, penicillin, phenytoin and phenobarbitol used for treating epilepsy, or the anesthetic halothane which can cause this disorder are discontinued. In affected individuals under 30 years of age, the disorder may initially be treated with the immune suppressant drug prednisone and/or antithymocyte globulin. The drugs cyclophosphamide, azathioprine, or 6-mercaptopurine which also suppress the immune system may be used for treating older individuals with Acquired Pure Red Cell Aplasia or those who fail to respond to steroids or antithymocyte globulin. Patients in both age groups may require periodic blood transfusions until the drugs take effect. The drug treatment is slowly decreased when remission of the disorder is acheived.

If an individual with Acquired Pure Red Cell Aplasia has a tumor of the thymus gland, surgical removal of this gland often causes remission of this disorder.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Clinical Trials and Studies

Scientists are studying a number of drugs that suppress the immune system in people with Acquired Pure Red Cell Aplasia. More studies are needed to determine the long-term safety and effectivness of these treatments.

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

References

TEXTBOOKS

Hematology Basic Principles and Practice, 2nd Ed.: Ronald Hoffman M.D., et. al., Editors; Churchill-Livingstone, Inc., 1995. Pp. 350-70.

JOURNAL ARTICLES

Pure Red Cell Aplasia Characterized by Erythropoietic Maturation Arrest. Response to Anti-Thymocyte Globulin. A.D. Jacobs et al.; American Journal Med (Mar 1985; 78(3)). Pp. 515-17.

New Therapies for Aplastic Anemia. S.B. Krantz; American Journal Med Sciences (1986; 291). Pp. 371-79.

Diphenylhydantoin-Induced Pure Red Cell Aplasia. E.N. Dessypris et al.; Blood (1985; 65). Pp. 789-94.

Brief Report: Autoantibodies Against Erythropoietin in a Patient with Pure Red-Cell Aplasia. N. Casadevall et al.; New Eng J Med (Mar 7 1996; 334(10)). Pp. 630-33.

Successful Treatment of a Patient with a Thymoma and Pure Red-Cell Aplasia with Octreotide and Prednisone. G. Palmieri et al.; New Eng J Med (Jan 23 1997; 336(4)). Pp. 263-65.

Acquired Pure Red Cell Aplasia in Japan. S. Mamiya et al.; Eur J Haematol (Oct 1997; 59(4)). Pp. 199-205.

  • < Previous section
  • Next section >

Programs & Resources

RareCare® Assistance Programs

NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.

Additional Assistance Programs

MedicAlert Assistance Program

NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.

Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/

Rare Disease Educational Support Program

Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.

Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/

Rare Caregiver Respite Program

This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.

Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/

Patient Organizations

No patient organizations found related to this disease state.


National Organization for Rare Disorders